FDA is temporarily exercising enforcement discretion with respect to certain Clozapine REMS program requirements to ensure continuity of care for patients taking clozapine

Full launch for the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program will not be implemented in 2016